Search results
Results from the WOW.Com Content Network
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran. [4] Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes. [6]
Idarucizumab [4] Praxbind: mab: humanized: dabigatran: Y: reversal of anticoagulant effects of dabigatran Ifabotuzumab [22] mab: humanized: EPHA3: glioblastoma multiforme [81] Igovomab: Indimacis-125: F(ab') 2: mouse: CA-125: ovarian cancer (diagnosis) Iladatuzumab vedotin [26] mab: humanized: CD79B: cancer Imalumab [6] mab: human: macrophage ...
Andexanet alfa, sold under the brand name Andexxa among others, is an antidote for the medications rivaroxaban and apixaban, when reversal of anticoagulation is needed due to uncontrolled bleeding. [8]
Idarucizumab [1] Boehringer Ingelheim: reversal of dabigatran: Asfotase alfa [1] Alexion Pharmaceuticals: perinatal/infantile/childhood hypophosphatasia: Osimertinib [1] AstraZeneca: EGFR-positive NSCLC: Daratumumab [1] Janssen Biotech: multiple myeloma: Nivolumab [1] Bristol-Myers Squibb: advanced renal cell carcinoma: Elotuzumab [1] Bristol ...
Ramucirumab([5]), sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer. [3] [4] Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist.
The number needed to treat (NNT) or number needed to treat for an additional beneficial outcome (NNTB) is an epidemiological measure used in communicating the effectiveness of a health-care intervention, typically a treatment with medication.
Ciraparantag significantly reverses anticoagulation induced by a therapeutic dose of edoxaban within 10 minutes following injection. [3] This return to normal haemostasis persists over 24 hours following a single intravenous dose of the drug. [4]
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). [4]